LEADER 00000cam  2200493Ia 4500 
001    ocn162131468 
003    OCoLC 
005    20110614113912.0 
006    m        d         
007    cr cn||||||||| 
008    070802s2006    ne a    ob    001 0 eng d 
020    9780444528063 
020    0444528067 
035    (OCoLC)162131468 
037    133878:134004|bElsevier Science & Technology|nhttp://
       www.sciencedirect.com 
040    OPELS|cOPELS|dOCLCG 
049    TEFA 
050 14 RB155.8|b.G46174 2006eb 
082 04 615.8/95|222 
096    QZ 52 G33 2006 
245 00 Gene therapy|h[electronic resource] :|bprospective 
       technology assessment in its societal context /|ceditors, 
       Jörg Niewöhner, Christof Tannert 
250    1st ed 
260    Amsterdam ;|aBoston :|bElsevier,|c2006 
300    xxii, 252 p. :|bill. (some col.) ;|c24 cm 
504    Includes bibliographical references and index 
505 0  Section I Scientific Aspects -- Section II Ethical and 
       Legal Aspects -- Section III Perception and Communication 
520    This book presents work that has been conducted as part of
       the research project "Discourse on ethical questions of 
       biomedicine" of the interdisciplinary Working Group 
       Bioethics and Science Communication at the Max-Delbrueck-
       Center for Molecular Medicine (MDC)in Berlin-Buch, 
       Germany. This book offers ground-breaking ideas on how the
       daily interworking of cutting-edge biomedical research 
       assess the broader social context and its communication to
       stakeholders and the public. Editors cover three aspects: 
       Scientific, Ethical and Legal, and Perception and 
       Communication. This work establishes an international and 
       interdisciplinary network of excellent researchers at the 
       beginning of their careers, who brilliantly integrate 
       their work into the different perspectives on gene therapy
       from the natural and social sciences, as well as the 
       humanities and law. * Discusses biological and cellular 
       barriers limiting the clinical application of nonviral 
       gene delivery systems * Addresses such questions as: Does 
       patent granting hinder the development of Gene Therapy 
       products? * Offers insight in the future of public 
       perception of gene therapy in Europe * Provides details on
       how to communicate risks in gene therapy 
533    Electronic reproduction.|bAmsterdam :|cElsevier Science & 
       Technology,|d2007.|nMode of access: World Wide Web.
       |nSystem requirements: Web browser.|nTitle from title 
       screen (viewed on July 25, 2007).|nAccess may be 
       restricted to users at subscribing institutions 
590    Elsevier 
650  0 Gene therapy 
650  0 Gene therapy|xSocial aspects 
650  2 Gene Therapy 
650  2 Gene Therapy|xtrends 
650  2 Gene Therapy|xethics 
650  2 Gene Therapy|xlegislation & jurisprudence 
650  2 Gene Transfer Techniques 
655  7 Electronic books.|2local 
700 1  Niewöhner, Jörg 
700 1  Tannert, Christof,|d1946- 
710 2  ScienceDirect (Online service) 
776 1  |cOriginal|z0444528067|z9780444528063|w(DLC)  2006046293
       |w(OCoLC)69594084 
856 40 |3ScienceDirect|uhttp://www.sciencedirect.com/science/book
       /9780444528063|zeBook(Elsevier)